-
11:36:50 PM

SESN Stock News

02/21/23 9:00 AM
Nasdaq : SESN
acquisition
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
Sesen Bio, Inc., today announced that leading independent proxy advisory firm Glass, Lewis& Co. recommends that stockholders vote“ FOR” all proposals, including the pending merger with Carisma Therapeutics Inc., in advance of the Company’ s upcoming Special Meeting of Stockholders scheduled for March 2, 2023. "...we believe it is reasonable to conclude that the...
RHEA-AI
positive
02/16/23 4:42 PM
Nasdaq : SESN
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
Sesen Bio, Inc., today announced that Institutional Shareholder Services recommends that stockholders vote“ FOR” all proposals, including the pending merger with Carisma Therapeutics Inc., at the Company’ s upcoming Special Meeting of Stockholders scheduled for March 2, 2023. “appears to have conducted a thorough overview of alternatives and is proposing to...
RHEA-AI
positive
02/16/23 8:00 AM
Nasdaq : SESN
conferencesacquisition
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
Sesen Bio, Inc. today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. management team on Tuesday, February 21, 2023, at 8:00 am ET. Sesen Bio stockholders can submit questions in advance to ir@sesenbio.com. The webcast, which can be accessed on the Events and Presentations link on the Sesen...
RHEA-AI
neutral
02/15/23 8:00 AM
Nasdaq : SESN
acquisition
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
Sesen Bio, Inc., today announced that BML Investment Partners, L.P., one of Sesen Bio’ s top stockholders, intends to vote all of its shares in support of the Company’ s pending merger with Carisma Therapeutics Inc.. With a substantial special cash dividend, enhanced CVR and exciting long-term potential of Carisma, we believe this represents the best path forward for...
RHEA-AI
positive
02/14/23 8:00 AM
Nasdaq : SESN
dividendsacquisition
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
Sesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement with Bradley L. Radoff and Michael Torok. In connection with the Support...
RHEA-AI
positive